March 23, 2022 -- Lucid Diagnostics, a Pavmed subsidiary, has launched Lucid Test Centers in Seattle, Portland, and Boise, ID. After physician referrals, patients can get tested for esophageal precancer at these centers.
The test centers are staffed with Lucid-employed nurse practitioners who use Lucid's EsoCheck cell collection device to collect surface esophageal cells. Then, the cells undergo Lucid's EsoGuard DNA esophageal test.
Lucid's tests serve as a screening tool to prevent esophageal cancer deaths through the early detection of esophageal precancer in at-risk gastroesophageal reflux disease patients.